Sun, 11 Aug 2013
Read the rest of this article on Morningstar Articles
Marsico Capital CEO Tom Marsico favors the growth prospects of these biotech companies that are producing novel drugs for unmet medical needs.
Investors might be looking to reallocate their assets as stocks continue to run up, but several large-cap equity funds could fit the bill.
It's unlikely we'll see the 6.5% long -run real returns of the past decades, but 4.0%-5.5% returns going forward shouldn't disappoint investors, says StockInvestor editor Matt Coffina.
StockInvestor editor Paul Larson details recent changes to Morningstar's Wide Moat Focus Index, noting how the rally in wide - moat names could have them more fairly priced than lower-quality stocks .
©2012 Morningstar Advisor. All right reserved.